WALTHAM, Mass. & BOULDER, Colo., January 20, 2026 — Cogent Biosciences announced that the U.S. Food and Drug Administration (FDA) has agreed to accept its New Drug Application (NDA) for bezuclastinib under the Real-Time Oncology Review (RTOR) program. The NDA seeks approval of bezuclastinib in combination with sunitinib for patients with gastrointestinal stromal tumors (GIST) who have progressed after prior treatment with imatinib, representing a major step forward in addressing a long-standing unmet need in oncology.
Science Significance
The NDA is supported by robust results from the PEAK Phase 3 clinical trial, the first-ever GIST study to demonstrate statistically significant superiority over an active comparator. The bezuclastinib plus sunitinib combination achieved a median progression-free survival (mPFS) of 16.5 months, compared with 9.2 months for sunitinib monotherapy, translating to a 50% reduction in the risk of disease progression or death. The trial also reported a 46% overall response rate (ORR) in imatinib-resistant patients, nearly doubling responses seen with standard therapy. These findings validate precision targeting of oncogenic KIT mutations as a scientifically meaningful strategy in advanced GIST.
Regulatory Significance
Acceptance under RTOR highlights the FDA’s recognition of both the strength of the clinical evidence and the urgent need for new therapies in imatinib-resistant GIST. RTOR enables rolling submission and early review of clinical data, potentially shortening regulatory timelines while maintaining rigorous evaluation standards. Cogent expects to initiate RTOR immediately, with completion of the PEAK NDA submission anticipated in April 2026. From a cGxP perspective, participation in RTOR reflects advanced readiness across GCP, GMP, and CMC domains, as early FDA engagement requires high levels of data quality, validation, and compliance.
Business Significance
Advertisement
For Cogent Biosciences, initiating an NDA under RTOR represents a transformational corporate milestone, positioning bezuclastinib as a potential first-in-class or best-in-class therapy for a defined GIST population. The program significantly enhances Cogent’s commercial outlook and long-term enterprise value, while reinforcing its strategy of developing precision therapies for genetically defined diseases. A successful RTOR pathway could enable earlier market entry, strengthening competitiveness in the oncology landscape and supporting future pipeline expansion.
Patients’ Significance
Patients with imatinib-resistant GIST have faced limited treatment advances for more than two decades. The PEAK trial data suggest that the bezuclastinib combination can deliver longer disease control and higher response rates without introducing unexpected safety risks. If approved, the therapy could redefine the standard of care, offering patients improved outcomes, extended progression-free survival, and renewed hope in a setting where therapeutic innovation has been scarce.
Policy Significance
This NDA submission underscores broader FDA policy initiatives to accelerate access to oncology therapies through programs such as RTOR. It reflects a regulatory shift toward earlier collaboration, rolling data review, and science-driven flexibility, particularly for serious and life-threatening diseases. The bezuclastinib case illustrates how strong clinical evidence, regulatory innovation, and GxP compliance can align to support faster availability of critical medicines.
The initiation of an NDA for bezuclastinib under the FDA’s Real-Time Oncology Review program marks a pivotal moment for Cogent Biosciences and the GIST treatment landscape. Backed by compelling PEAK trial results and enabled by an accelerated regulatory pathway, the program highlights the growing impact of precision oncology and modernized drug review frameworks. As the application progresses toward completion in 2026, bezuclastinib stands poised to become a meaningful advancement for patients, regulators, and the broader pharmaceutical ecosystem.
Source: Cogent Biosciences press release
